João Victor Vanolli Protti

Mr. João Victor Vanolli Protti

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
WMWallace Morais
Wallace Morais
GCGustavo Oliveira Costa
Gustavo Oliveira Costa
VPVinicius Leal Pitcella
Vinicius Leal Pitcella
JPJoão Victor Vanolli Protti
João Victor Vanolli Protti
CMCarolina Paula de Souza Moreira
Carolina Paula de Souza Moreira
RORenata Oliveira
Renata Oliveira
Fungal infections have become a growing concern in healthcare, particularly in immuno-compromised individuals, with species like Candida, Cryptococcus, and Sporothrix pos-ing significant challenges due to rising resistance and limited treatment options. In re-sponse, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve water solubility and pharmacokinetic properties. The com-pound demonstrated a broad antifungal spectrum, particularly effective against Crypto-coccus neoformans and Candida auris, with minimal irritant potential and low cytotoxi-city. RW3 showed favorable solubility and high intestinal permeability, indicating poten-tial for oral administration. The results suggest RW3 as a promising lead for further de-velopment as a therapeutic agent for systemic fungal infections. These findings under-score the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.

16 January 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
WMWallace Cordeiro de Morais
Wallace Cordeiro de Morais
GCGustavo Oliveira Costa
Gustavo Oliveira Costa
VPVinicius Leal Pitcella
Vinicius Leal Pitcella
JPJoão Victor Vanolli Protti
João Victor Vanolli Protti
CMCarolina Paula de Souza Moreira
Carolina Paula de Souza Moreira
RORenata Oliveira
Renata Oliveira
Fungal infections have become a growing concern in healthcare, particularly in immunocompromised individuals, with species like Candida, Cryptococcus, and Sporothrix posing significant challenges due to rising resistance and limited treatment options. In response, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve its water solubility and pharmacokinetic properties. The compound demonstrated a broad antifungal spectrum, particularly effective against Cryptococcus neoformans and Candida auris, with minimal irritant potential and low cytotoxicity. RW3 showed favorable solubility and high intestinal permeability, indicating potential for oral administration. The results suggest RW3 as a promising lead for further development as a therapeutic agent for systemic fungal infections. These findings underscore the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.